Liquidia raises $100M: $75M equity private placement + $25M debt from HCR
Liquidia Corp
- Private placement of 7,182,532 shares at $10.442/share (8% discount to Jan 3 close) to Patient Square Capital affiliate; gross proceeds ~$75M.
- Fourth amendment to RIFA funds additional $25M from HCR, bringing total drawn to $67.5M; remaining $32.5M available upon mutual agreement.
- CFO says combined $126M (including Dec 2023 offerings) positions company to reach profitability if YUTREPIA launches by April 2024.
- Proceeds to fund commercial development, clinical trials for YUTREPIA (PAH/PH-ILD) and L606, plus general corporate purposes.
- Equity issuance expected to close January 8, 2024; no broker fees paid.